Abeona Therapeutics (NASDAQ:ABEO) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a research note released on Thursday.

A number of other equities analysts also recently weighed in on ABEO. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday.

Abeona Therapeutics Trading Up 6.3 %

Shares of ABEO stock opened at $6.41 on Thursday. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01. The company has a market capitalization of $278.64 million, a P/E ratio of -2.38 and a beta of 1.52. The firm has a 50-day moving average price of $6.24 and a 200 day moving average price of $5.32. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rosalind Advisors Inc. raised its stake in shares of Abeona Therapeutics by 4.7% during the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after buying an additional 82,000 shares during the last quarter. Western Standard LLC raised its stake in shares of Abeona Therapeutics by 7.0% during the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after buying an additional 110,998 shares during the last quarter. Citigroup Inc. raised its stake in shares of Abeona Therapeutics by 10.1% during the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after buying an additional 56,332 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after buying an additional 429,456 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after buying an additional 83,050 shares during the last quarter. 80.56% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.